Emerging repair, regeneration, and translational research advances for spinal cord injury

Spine

Volumn 35, Issue 21 SUPPL., 2010, Pages

  Kwon, Brian K ^a   Sekhon, Lali H ^b   Fehlings, Michael G ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SpineNevada   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

clinical trials; spinal cord injury; translational research

Indexed keywords

CETHRIN; ENZYME INHIBITOR; MAGNESIUM CHLORIDE; MINOCYCLINE; NOGO A ANTIBODY; RILUZOLE; UNCLASSIFIED DRUG;

CLINICAL RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTHERMIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPINAL CORD INJURY; SYSTEMATIC REVIEW;

ANIMALS; HUMANS; RECOVERY OF FUNCTION; REGENERATION; SPINAL CORD; SPINAL CORD INJURIES; THERAPIES, INVESTIGATIONAL; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

EID: 77958013407     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181f3286d     Document Type: Review

References (84)

1. Spinal cord injury, facts and figures at a glance. J Spinal Cord Med 2008;31: 357-358
2. One Degree of Separation; Paralysis and Spinal Cord Injury in the United States. Short Hills, NJ: Christopher and Dana Reeve Foundation; 2009.
3. Hurlbert RJ, Hamilton MG. Methylprednisolone for acute spinal cord injury: 5-year practice reversal. Can J Neurol Sci 2008;35:41-45
4. Eck JC, Nachtigall D, Humphreys SC, et al. Questionnaire survey of spine surgeons on the use of methylprednisolone for acute spinal cord injury. Spine (Phila Pa 1976) 2006;31:E250-3.
5. Tator CH. Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 2006;59:957-982
6. Hawryluk GW, Rowland J, Kwon BK, et al. Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus 2008;25:E14.
7. Baptiste DC, Fehlings MG. Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs 2008;13:63-80.
8. Mann CM, Kwon BK. An update on the pathophysiology of acute spinal cord injury. Sem Spine Surg 2007;19:272-279
9. Rowland JW, Hawryluk GW, Kwon B, et al. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus 2008;25:E2.
10. The Consortium for Spinal Cord Medicine. Early Acute Management in Adults with Spinal Cord Injury: A Clinical Practice Guideline for Health Care Providers. Washington, DC: Paralyzed Veterans of America; 2009.
11. Fehlings MG, Tator CH, Linden RD. The effect of nimodipine and dextran on axonal function and blood flow following experimental spinal cord injury. J Neurosurg 1989;71:403-416
12. Ross IB, Tator CH. Further studies of nimodipine in experimental spinal cord injury in the rat. J Neurotrauma 1991;8:229-238
13. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991;75:15-26.
14. Gaviria M, Privat A, D'Arbigny P, et al. Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats. Brain Res 2000;874:200-209
15. Bracken MB, Collins WF, Freeman DF, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984;251:45-52.
16. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322:1405-1411
17. Bracken MB, Shepard MJ, Holford TR, et al; National Acute Spinal Cord Injury Study. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. JAMA 1997;277:1597-1604
18. Kwon BK, Borisoff JF, Tetzlaff W. Molecular targets for intervention in spinal cord injury. Mol Interv 2002;2:244-258
19. Fitch MT, Silver J. CNS injury, glial scars, and inflammation: inhibitory extracellular matrices and regeneration failure. Exp Neurol 2008;209:294-301.
20. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci 2004;5:146-156
21. Hill CE, Beattie MS, Bresnahan JC. Degeneration and sprouting of identified descending supraspinal axons after contusive spinal cord injury in the rat. Exp Neurol 2001;171:153-169
22. Kakulas BA. A review of the neuropathology of human spinal cord injury with emphasis on special features. J Spinal Cord Med 1999;22:119-124
23. Guest JD, Hiester ED, Bunge RP. Demyelination and Schwann cell responses adjacent to injury epicenter cavities following chronic human spinal cord injury. Exp Neurol 2005;192:384-393
24. Caroni P, Schwab ME. Two membrane protein fractions from rat central myelin with inhibitory properties for neurite growth and fibroblast spreading. J Cell Biol 1988;106:1281-1288
25. Schwab ME, Caroni P. Oligodendrocytes and CNS myelin are nonpermissive substrates for neurite growth and fibroblast spreading in vitro. J Neurosci 1988;8:2381-2393
26. Caroni P, Schwab ME. Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron 1988;1:85-96.
27. Schnell L, Schwab ME. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 1990;343:269-272
28. Bregman BS, Kunkel-Bagden E, Schnell L, et al. Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature 1995; 378:498-501.
29. Fouad K, Dietz V, Schwab ME. Improving axonal growth and functional recovery after experimental spinal cord injury by neutralizing myelin associated inhibitors. Brain Res Brain Res Rev 2001;36:204-212
30. Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1 [comments]. Nature 2000;403:434-439
31. GrandPre T, Nakamura F, Vartanian T, et al. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000;403: 439-444
32. Prinjha R, Moore SE, Vinson M, et al. Inhibitor of neurite outgrowth in humans. Nature 2000;403:383-384
33. Freund P, Schmidlin E, Wannier T, et al. Anti-Nogo-A antibody treatment promotes recovery of manual dexterity after unilateral cervical lesion in adult primates-re-examination and extension of behavioral data. Eur J Neurosci 2009;29:983-996
34. Wannier-Morino P, Schmidlin E, Freund P, et al. Fate of rubrospinal neurons after unilateral section of the cervical spinal cord in adult macaque monkeys: effects of an antibody treatment neutralizing Nogo-A. Brain Res 2008;1217: 96-109.
35. Freund P, Wannier T, Schmidlin E, et al. Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey. J Comp Neurol 2007;502:644-659
36. Liebscher T, Schnell L, Schnell D, et al. Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann Neurol 2005;58:706-719
37. McKerracher L, Higuchi H. Targeting Rho to stimulate repair after spinal cord injury. J Neurotrauma 2006;23:309-317
38. Dergham P, Ellezam B, Essagian C, et al. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 2002;22:6570-6577
39. Dubreuil CI, Winton MJ, McKerracher L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J Cell Biol 2003;162:233-243
40. Bertrand J, Winton MJ, Rodriguez-Hernandez N, et al. Application of Rho antagonist to neuronal cell bodies promotes neurite growth in compartmented cultures and regeneration of retinal ganglion cell axons in the optic nerve of adult rats. J Neurosci 2005;25:1113-1121
41. Stirling DP, Koochesfahani KM, Steeves JD, et al. Minocycline as a neuroprotective agent. Neuroscientist 2005;11:308-322
42. Heo K, Cho YJ, Cho KJ, et al. Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice. Neurosci Lett 2006; 398:195-200.
43. Yune TY, Lee JY, Jung GY, et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 2007;27:7751-7761
44. Festoff BW, Ameenuddin S, Arnold PM, et al. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 2006;97:1314-1326
45. Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004;24:2182-2190
46. Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusiontriggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A 2004;101:3071-3076
47. Lee SM, Yune TY, Kim SJ, et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003;20:1017-1027
48. Wells JE, Hurlbert RJ, Fehlings MG, et al. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003; 126:1628-1637
49. Pinzon A, Marcillo A, Quintana A, et al. A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res 2008;1243:146-151
50. Saganova K, Orendacova J, Cizkova D, et al. Limited minocycline neuroprotection after balloon-compression spinal cord injury in the rat. Neurosci Lett 2008;433:246-249
51. Inamasu J, Ichikizaki K. Mild hypothermia in neurologic emergency: an update. Ann Emerg Med 2002;40:220-230
52. Erecinska M, Thoresen M, Silver IA. Effects of hypothermia on energy metabolism in mammalian central nervous system. J Cereb Blood Flow Metab 2003;23:513-530
53. Kwon BK, Mann C, Sohn HM, et al. Hypothermia for spinal cord injury. Spine J 2008;8:859-874
54. Yu CG, Jimenez O, Marcillo AE, et al. Beneficial effects of modest systemic hypothermia on locomotor function and histopathological damage following contusion-induced spinal cord injury in rats. J Neurosurg 2000;93:85-93.
55. Westergren H, Farooque M, Olsson Y, et al. Motor function changes in the rat following severe spinal cord injury. Does treatment with moderate systemic hypothermia improve functional outcome? Acta Neurochir (Wien) 2000;142:567-573
56. Layden T. Kevin Everett, the road back. Sports Illus 2007;107:56-67. 12- 17-2007.
57. Levi AD, Green BA, Wang MY, et al. Clinical application of modest hypothermia after spinal cord injury. J Neurotrauma 2009;26:407-415
58. Levi AD, Casella G, Green BA, et al. Clinical outcomes using modest intravascular hypothermia after acute cervical spinal cord injury. Neurosurgery 2010;66:670-677
59. Agrawal SK, Fehlings MG. The effect of the sodium channel blocker QX-314 on recovery after acute spinal cord injury. J Neurotrauma 1997;14:81-88
60. Agrawal SK, Fehlings MG. Mechanisms of secondary injury to spinal cord axons in vitro: role of Na+, Na(+)-K(+)-ATPase, the Na(+)-H+ exchanger, and the Na(+)-Ca2+ exchanger. J Neurosci 1996;16:545-552
61. Rosenberg LJ, Wrathall JR. Time course studies on the effectiveness of tetrodotoxin in reducing consequences of spinal cord contusion. J Neurosci Res 2001;66:191-202.
62. Rosenberg LJ, Teng YD, Wrathall JR. Effects of the sodium channel blocker tetrodotoxin on acute white matter pathology after experimental contusive spinal cord injury. J Neurosci 1999;19:6122-6133
63. Ates O, Cayli SR, Gurses I, et al. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J Clin Neurosci 2007;14:658-665
64. McAdoo DJ, Hughes MG, Nie L, et al. The effect of glutamate receptor blockers on glutamate release following spinal cord injury. Lack of evidence for an ongoing feedback cascade of damage 224 glutamate release 224 damage 224 glutamate release 224 etc. Brain Res 2005;1038:92-99
65. Schwartz G, Fehlings MG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg 2001;94:245-256
66. Mu X, Azbill RD, Springer JE. Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury. J Neurotrauma 2000;17:773-780
67. Mu X, Azbill RD, Springer JE. Riluzole improves measures of oxidative stress following traumatic spinal cord injury. Brain Res 2000;870:66-72.
68. Springer JE, Azbill RD, Kennedy SE, et al. Rapid calpain I activation and cytoskeletal protein degradation following traumatic spinal cord injury: attenuation with riluzole pretreatment. J Neurochem 1997;69:1592-1600
69. Stutzmann JM, Pratt J, Boraud T, et al. The effect of riluzole on posttraumatic spinal cord injury in the rat. Neuroreport 1996;7:387-392
70. Choi DW. Excitotoxic cell death. J Neurobiol 1992;23:1261-1276
71. Faden AI, Demediuk P, Panter SS, et al. The role of excitatory amino acids andNMDAreceptors in traumatic brain injury. Science 1989;244:798-800.
72. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2001;2:241-271
73. Vink R, Cernak I. Regulation of intracellular free magnesium in central nervous system injury. Front Biosci 2000;5:D656-65.
74. Lemke M, Faden AI. Edema development and ion changes in rat spinal cord after impact trauma: injury dose-response studies. J Neurotrauma 1990;7: 41-54.
75. Vink R, McIntosh TK, Demediuk P, et al. Decrease in total and free magnesium concentration following traumatic brain injury in rats. Biochem Biophys Res Commun 1987;149:594-599
76. Mendez DR, Corbett R, Macias C, et al. Total and ionized plasma magnesium concentrations in children after traumatic brain injury. Pediatr Res 2005;57:347-352
77. Kwon BK, Roy J, Lee JH, et al. Magnesium chloride in a polyethylene glycol formulation as a neuroprotective therapy for acute spinal cord injury: preclinical refinement and optimization. J Neurotrauma 2009;26:1379-1393
78. Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol 2007;6:29-38.
79. Keirstead HS, Nistor G, Bernal G, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 2005;25:4694-4705
80. Hofstetter CP, Holmstrom NA, Lilja JA, et al. Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome. Nat Neurosci 2005;8:346-353
81. Karimi-Abdolrezaee S, Eftekharpour E, Wang J, et al. Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. J Neurosci 2006;26:3377-3389
82. Study Using Embryonic Stem Cells Is Delayed, New York Times, August 19, 2009. http://www.nytimes.com/2009/08/19/health/research/ 19drug.html?-r- 1&ref-geron-corporation.
83. Geisler FH, Coleman WP, Grieco G, et al. The Sygen multicenter acute spinal cord injury study. Spine 2001;26:S87-98.
84. Fawcett JW, Curt A, Steeves JD, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007;45:190-205.